CO6270304A2 - N-{4-(2,2-dimetil-propiomil)-(5r)-5-[(2-etilamino-etanosulfonil amino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil propionamida - Google Patents

N-{4-(2,2-dimetil-propiomil)-(5r)-5-[(2-etilamino-etanosulfonil amino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil propionamida

Info

Publication number
CO6270304A2
CO6270304A2 CO10001885A CO10001885A CO6270304A2 CO 6270304 A2 CO6270304 A2 CO 6270304A2 CO 10001885 A CO10001885 A CO 10001885A CO 10001885 A CO10001885 A CO 10001885A CO 6270304 A2 CO6270304 A2 CO 6270304A2
Authority
CO
Colombia
Prior art keywords
dimethyl
dihydro
phenyl
propiomil
ethanosulphonyl
Prior art date
Application number
CO10001885A
Other languages
English (en)
Inventor
Hiroko Kusano
Dinesh Shiamdeo Mishra
Yoshikazu Tashiro
Yosuke Watanabe
Hong Zhuang
Original Assignee
Lilly Co Eli
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6270304(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Kyowa Hakko Kirin Co Ltd filed Critical Lilly Co Eli
Publication of CO6270304A2 publication Critical patent/CO6270304A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Una composicion farmacéutica, caracterizada porque comprende N-{4-(2,2- dimetil-propionil)-(5R)-5-[(2-etilamino-etanosulfonilamino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}--2,2-dimetil-propionamida, un buffer y/o sal seleccionada entre tartrato, fosfato, citrato, mesilato, fosfato de sodio, y sulfato de sodio, y un vehiculo, diluyente o excipiente en solucion acuosa en donde el pH de dicha composicion es menor que 5.4 y mayor que 2.0 y contiene no mas de 2.0% de -{4-(2,2-dimetil-propionil)-(5R)-5-[(2-etilamino-etanosulfonilamino)-metil]-5-fenil-4.5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil-propionamida y es estable a la conversion quiral.2.- La composicion farmacéutica de la Reivindicacion 1 en donde el buffer y/o sal se selecciona entre tartrato, fosfato, citrato y fosfato de sodio.3.- La composicion farmacéutica de la Reivindicacion 2 en donde el buffer y/o sal se selecciona entre tartrato y fosfato de sodio.4.- La composicion farmacéutica de la Reivindicacion 3 en donde el buffer y/o sal es tartrato.
CO10001885A 2007-07-12 2010-01-08 N-{4-(2,2-dimetil-propiomil)-(5r)-5-[(2-etilamino-etanosulfonil amino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil propionamida CO6270304A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94926807P 2007-07-12 2007-07-12

Publications (1)

Publication Number Publication Date
CO6270304A2 true CO6270304A2 (es) 2011-04-20

Family

ID=39735000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10001885A CO6270304A2 (es) 2007-07-12 2010-01-08 N-{4-(2,2-dimetil-propiomil)-(5r)-5-[(2-etilamino-etanosulfonil amino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil propionamida

Country Status (28)

Country Link
US (1) US8222284B2 (es)
EP (1) EP2178508B1 (es)
JP (1) JP4875205B2 (es)
KR (1) KR101188036B1 (es)
CN (1) CN101730525A (es)
AR (1) AR067472A1 (es)
AU (1) AU2008275258A1 (es)
BR (1) BRPI0814039A2 (es)
CA (1) CA2694277C (es)
CL (1) CL2008001996A1 (es)
CO (1) CO6270304A2 (es)
CR (1) CR11210A (es)
DO (1) DOP2010000004A (es)
EA (1) EA016861B1 (es)
EC (1) ECSP109864A (es)
ES (1) ES2401477T3 (es)
GT (1) GT201000003A (es)
HK (1) HK1141238A1 (es)
IL (1) IL202382A0 (es)
MA (1) MA31880B1 (es)
MX (1) MX2010000468A (es)
NZ (1) NZ581791A (es)
PE (1) PE20090438A1 (es)
SV (1) SV2010003449A (es)
TN (1) TN2010000015A1 (es)
TW (1) TW200918050A (es)
UA (1) UA97672C2 (es)
WO (1) WO2009009470A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447536B1 (en) 2009-06-26 2017-12-27 Mitsubishi Electric Corporation Refrigerant compressor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051854A1 (en) 2001-12-11 2003-06-26 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
ATE537158T1 (de) * 2003-04-18 2011-12-15 Kyowa Hakko Kirin Co Ltd M-stage-kinesin-inhibitor
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
KR20070114822A (ko) * 2005-03-22 2007-12-04 교와 핫꼬 고교 가부시끼가이샤 조혈기 종양 치료제
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
AU2006225636A1 (en) 2005-03-22 2006-09-28 Fujifilm Corporation Therapeutic agent for solid tumor
US7910611B2 (en) * 2005-06-24 2011-03-22 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for restenosis

Also Published As

Publication number Publication date
CA2694277A1 (en) 2009-01-15
CA2694277C (en) 2013-04-09
US20110009458A1 (en) 2011-01-13
CR11210A (es) 2010-06-23
JP2010533190A (ja) 2010-10-21
EA201070136A1 (ru) 2010-06-30
KR101188036B1 (ko) 2012-10-05
JP4875205B2 (ja) 2012-02-15
CL2008001996A1 (es) 2009-05-22
IL202382A0 (en) 2010-06-30
WO2009009470A1 (en) 2009-01-15
DOP2010000004A (es) 2010-03-15
GT201000003A (es) 2012-03-13
EP2178508A1 (en) 2010-04-28
HK1141238A1 (en) 2010-11-05
ES2401477T3 (es) 2013-04-19
MX2010000468A (es) 2010-04-09
TW200918050A (en) 2009-05-01
AR067472A1 (es) 2009-10-14
NZ581791A (en) 2012-03-30
SV2010003449A (es) 2010-08-10
AU2008275258A1 (en) 2009-01-15
EP2178508B1 (en) 2013-02-06
UA97672C2 (ru) 2012-03-12
TN2010000015A1 (en) 2011-09-26
KR20100029827A (ko) 2010-03-17
ECSP109864A (es) 2010-03-31
BRPI0814039A2 (pt) 2017-10-03
EA016861B1 (ru) 2012-08-30
MA31880B1 (fr) 2010-12-01
US8222284B2 (en) 2012-07-17
CN101730525A (zh) 2010-06-09
PE20090438A1 (es) 2009-04-18

Similar Documents

Publication Publication Date Title
FIC20200014I1 (fi) Fostamatinibi tai fostamatinibin farmaseuttisesti hyväksyttävä suola tai fostamatinibin hydraatti, solvaatti, tai N-oksidi, tai fostamatinibin farmaseuttisesti hyväksyttävä suola, erityisesti fostamatinibi dinatrium, valinnaisesti hydraatin muodossa
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MX2014002113A (es) Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
BRPI0708038B8 (pt) derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
EA200870019A1 (ru) Лактамовые соединения и способы их применения
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
ITMI20050328A1 (it) Composti peptidomimetrici e preparazione di derivati biologicamente attivi
PE20061319A1 (es) Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
CY1111390T1 (el) Μεθοδος θεραπευτικης αγωγης καρκινου
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
BRPI0409867A (pt) composição farmacêutica contendo lactato e usos da mesma
EA200800810A1 (ru) Соль глюкуроновой кислоты и соединения пиперазина
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
CO6270304A2 (es) N-{4-(2,2-dimetil-propiomil)-(5r)-5-[(2-etilamino-etanosulfonil amino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil propionamida
ATE548043T1 (de) Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin
NO20075080L (no) Pyridylmetylsulfonderivater
NO20074371L (no) Anthelmintiske imidazol-tiazolderivater

Legal Events

Date Code Title Description
FG Application granted